BRIEF-Ani Pharmaceuticals Announces Results From New Day Clinical Trial Of Iluvien® For Use In Patients With Diabetic Macular Edema (Dme)

Reuters

Jul 23

BRIEF-Ani Pharmaceuticals Announces Results From New Day Clinical Trial Of Iluvien® For Use In Patients With Diabetic Macular Edema (Dme)

July 23 (Reuters) - ANI Pharmaceuticals Inc ANIP.O:

ANI PHARMACEUTICALS ANNOUNCES RESULTS FROM NEW DAY CLINICAL TRIAL OF ILUVIEN® FOR USE IN PATIENTS WITH DIABETIC MACULAR EDEMA $(DME.AU)$
ANI PHARMACEUTICALS INC - PRIMARY ENDPOINT WAS MEAN NUMBER OF SUPPLEMENTAL AFLIBERCEPT INJECTIONS
ANI PHARMACEUTICALS INC - ILUVIEN SHOWED NUMERICAL REDUCTION IN INJECTIONS BUT NOT SIGNIFICANT
ANI PHARMACEUTICALS INC - SECONDARY ENDPOINT MET WITH MEAN TIME OF 185.4 DAYS IN ILUVIEN ARM
ANI PHARMACEUTICALS INC - ILUVIEN WELL TOLERATED WITH CONSISTENT SAFETY PROFILE IN TRIAL

Source text: ID:nGNX7cSqJ3

Further company coverage: ANIP.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2553098214"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553098214\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553098214?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-23 18:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553098214","market":"fut","top_or_hot":-1,"title":"BRIEF-Ani Pharmaceuticals Announces Results From New Day Clinical Trial Of Iluvien® For Use In Patients With Diabetic Macular Edema (Dme)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Ani Pharmaceuticals Announces Results From New Day Clinical Trial Of Iluvien® For Use In Patients With Diabetic Macular Edema (Dme)</title></head><body><p><span>July 23 (Reuters)</span><span> - </span>ANI Pharmaceuticals Inc <span>ANIP.O</span>:</p><ul><li><p>ANI PHARMACEUTICALS ANNOUNCES RESULTS FROM NEW DAY CLINICAL TRIAL OF ILUVIEN® FOR USE IN PATIENTS WITH DIABETIC MACULAR EDEMA <a href=\"https://laohu8.com/S/DME.AU\">$(DME.AU)$</a></p></li><li><p>ANI PHARMACEUTICALS INC - PRIMARY ENDPOINT WAS MEAN NUMBER OF SUPPLEMENTAL AFLIBERCEPT INJECTIONS</p></li><li><p>ANI PHARMACEUTICALS INC - ILUVIEN SHOWED NUMERICAL REDUCTION IN INJECTIONS BUT NOT SIGNIFICANT</p></li><li><p>ANI PHARMACEUTICALS INC - SECONDARY ENDPOINT MET WITH MEAN TIME OF 185.4 DAYS IN ILUVIEN ARM</p></li><li><p>ANI PHARMACEUTICALS INC - ILUVIEN WELL TOLERATED WITH CONSISTENT SAFETY PROFILE IN TRIAL</p></li></ul><p>Source text: <span>ID:nGNX7cSqJ3</span></p><p>Further company coverage: <span>ANIP.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ani Pharmaceuticals Announces Results From New Day Clinical Trial Of Iluvien® For Use In Patients With Diabetic Macular Edema (Dme)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ani Pharmaceuticals Announces Results From New Day Clinical Trial Of Iluvien® For Use In Patients With Diabetic Macular Edema (Dme)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-23 18:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Ani Pharmaceuticals Announces Results From New Day Clinical Trial Of Iluvien® For Use In Patients With Diabetic Macular Edema (Dme)</title></head><body><p><span>July 23 (Reuters)</span><span> - </span>ANI Pharmaceuticals Inc <span>ANIP.O</span>:</p><ul><li><p>ANI PHARMACEUTICALS ANNOUNCES RESULTS FROM NEW DAY CLINICAL TRIAL OF ILUVIEN® FOR USE IN PATIENTS WITH DIABETIC MACULAR EDEMA <a href=\"https://laohu8.com/S/DME.AU\">$(DME.AU)$</a></p></li><li><p>ANI PHARMACEUTICALS INC - PRIMARY ENDPOINT WAS MEAN NUMBER OF SUPPLEMENTAL AFLIBERCEPT INJECTIONS</p></li><li><p>ANI PHARMACEUTICALS INC - ILUVIEN SHOWED NUMERICAL REDUCTION IN INJECTIONS BUT NOT SIGNIFICANT</p></li><li><p>ANI PHARMACEUTICALS INC - SECONDARY ENDPOINT MET WITH MEAN TIME OF 185.4 DAYS IN ILUVIEN ARM</p></li><li><p>ANI PHARMACEUTICALS INC - ILUVIEN WELL TOLERATED WITH CONSISTENT SAFETY PROFILE IN TRIAL</p></li></ul><p>Source text: <span>ID:nGNX7cSqJ3</span></p><p>Further company coverage: <span>ANIP.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0566484027.USD","symbol_name":"安本美国小盘成长股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nTUA6G7QLZ:1","article_id":"2553098214","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553098214","pubTimestamp":1753268049,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Ani Pharmaceuticals Announces Results From New Day Clinical Trial Of Iluvien For Use In Patients With Diabetic Macular Edema (Dme)July 23 (Reuters) - ANI Pharmaceuticals Inc ANIP.O:ANI PHARMACEU","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0566484027.USD":"安本美国小盘成长股","ANIP":"ANI Pharmaceuticals, Inc.","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4007":"制药"},"translate_title":"简介-Ani Pharmaceuticals公布Iluvien新一天临床试验结果®用于糖尿病性黄斑水肿(Dme)患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":0.9},"content_text":"BRIEF-Ani Pharmaceuticals Announces Results From New Day Clinical Trial Of Iluvien® For Use In Patients With Diabetic Macular Edema (Dme)July 23 (Reuters) - ANI Pharmaceuticals Inc ANIP.O:ANI PHARMACEUTICALS ANNOUNCES RESULTS FROM NEW DAY CLINICAL TRIAL OF ILUVIEN® FOR USE IN PATIENTS WITH DIABETIC MACULAR EDEMA $(DME.AU)$ANI PHARMACEUTICALS INC - PRIMARY ENDPOINT WAS MEAN NUMBER OF SUPPLEMENTAL AFLIBERCEPT INJECTIONSANI PHARMACEUTICALS INC - ILUVIEN SHOWED NUMERICAL REDUCTION IN INJECTIONS BUT NOT SIGNIFICANTANI PHARMACEUTICALS INC - SECONDARY ENDPOINT MET WITH MEAN TIME OF 185.4 DAYS IN ILUVIEN ARMANI PHARMACEUTICALS INC - ILUVIEN WELL TOLERATED WITH CONSISTENT SAFETY PROFILE IN TRIALSource text: ID:nGNX7cSqJ3Further company coverage: ANIP.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}